Resource Logo
Gay Men's Health Crisis

DRUG WATCH: First Human Data on Effectiveness of Antisense Drugs


GMHC Treatment Issues 1994 Jun 1; 8(4): 7

Isis Pharmaceuticals of San Diego is reporting encouraging preliminary data on its antisense compound aimed at CMV, blocking a gene necessary for the virus's reproduction. The drug, ISIS 2922, is injected weekly into the patients' eyes to arrest CMV retinitis. CMV-associated retinal lesions resolved (leaving inactive patches) in all five members of the ISIS 2922 trial's high-dose arm. The same happened to two of three volunteers receiving the medium dose. There have been no relapses so far in up to four months of treatment. All these patients had failed or become intolerant of the standard CMV therapies, ganciclovir and foscarnet. Despite these positive results (which were publicized by the company's PR department), Isis insists that it is premature to begin a compassionate use program for people outside of the Isis trials who are doing poorly on the approved CMV retinitis medications.

Copyright (c) 1994 - GMHC Treatment Issues. Noncommercial reproduction encouraged. Distributed by AEGIS, your online gateway to a world of people, knowledge, and resources. Direct Dial: v.34+: 714.248.2836; v.120/ISDN: 714.248.0433 Internet: www:


Copyright © 1994 -Gay Men's Health Crisis, Publisher. All rights reserved to Gay Men's Health Crisis (GMHC) Treatment Issues. Reproduced with permission. Treatment Issues is published twelve times yearly by GMHC, INC. Noncommercial reproduction is encouraged. Subscription lists are kept confidential. GMHC Treatment Issues, The Tisch Building, 119 West 24th Street, New York, NY 10011 Email GMHC. Visit GMHC

Information in this article was accurate in June 1, 1994. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.